Wedbush Issues Positive Forecast for Pharvaris (NASDAQ:PHVS) Stock Price

Pharvaris (NASDAQ:PHVS) had its price target increased by Wedbush from $41.00 to $42.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other brokerages have also issued reports on PHVS. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Royal Bank Of Canada reduced their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.80.

Pharvaris Stock Down 1.9%

Shares of NASDAQ:PHVS opened at $27.84 on Tuesday. The firm has a fifty day moving average of $27.08 and a two-hundred day moving average of $25.48. The firm has a market capitalization of $1.51 billion, a P/E ratio of -8.26 and a beta of -2.58. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.85.

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL acquired a new stake in Pharvaris in the 3rd quarter worth approximately $1,943,000. TFG Asset Management GP Ltd lifted its position in Pharvaris by 48.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock worth $3,311,000 after acquiring an additional 61,105 shares during the last quarter. Boothbay Fund Management LLC lifted its position in Pharvaris by 735.1% during the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after acquiring an additional 118,994 shares during the last quarter. General Atlantic L.P. lifted its position in Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares during the last quarter. Finally, Baker BROS. Advisors LP acquired a new position in Pharvaris during the 3rd quarter worth $9,356,000.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wedbush raised its price target to $42 and kept an “outperform” rating, implying roughly a 50% upside from current levels — a near-term bullish catalyst from an influential equity shop. Benzinga
• Positive Sentiment: HC Wainwright issued long-range FY2030 estimates calling for EPS of $5.37 and maintains a “Buy” rating with a $60 target — a highly constructive, bullish long-term projection that signals analysts expect strong eventual profitability. MarketBeat
• Neutral Sentiment: Brokerage consensus remains favorable overall — PHVS is reported to have an average rating of “Moderate Buy,” reflecting broad analyst support but varied views on timing and magnitude of upside. American Banking News
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $52 to $51 but left an “outperform” rating in place — a small downgrade in projection that still implies large upside, so its market impact is muted. Benzinga
• Negative Sentiment: Coverage and commentary are questioning whether Phase 3 completion and projected 2025 losses change Pharvaris’ investment narrative; concerns about near-term profitability and how the market will value post‑Phase 3 commercialization are weighing on sentiment. Yahoo Finance

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.